Korea's Samsung And Pfizer In Genome Research Partnership To Fight Liver Cancer
This article was originally published in PharmAsia News
Executive Summary
SEOUL - A month after an announcement about entering the biosimilars sector, South Korea's leading conglomerate, Samsung Group, is gearing up to get a stronger foothold in the pharmaceutical industry through establishing connections with established players